CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

FDA Biologics (BLA & Biosimilars)
High ImpactOriginal article

REBINYN

RegulatoryapprovedREBINYNPositive
AI Analysis

Summary

REBINYN received FDA approval for treatment of acute bleeding episodes in congenital fibrinogen deficiency and for on-demand treatment in hemophilia B patients.

Outcome Details

Product approval for treatment of acute bleeding episodes in congenital fibrinogen deficiency and hemophilia B

Importance:8/10
Sentiment:
0.80
FDA approvalhemophilia Bfibrinogen deficiencybiologics

Read the original article

Published by FDA Biologics (BLA & Biosimilars) on September 9, 2026 3:00 PM

Read Original